XML 65 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1
Collaboration Agreements (Details)
1 Months Ended 12 Months Ended
Mar. 31, 2014
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2016
CAD
Dec. 31, 2015
USD ($)
Dec. 31, 2015
CAD
Dec. 31, 2014
USD ($)
Dec. 31, 2014
CAD
Dec. 31, 2012
USD ($)
Dec. 31, 2011
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Upfront payment performance description   The Company determined that the $1,500 upfront payment should be recognized as revenue ratably over the expected period of performance, being the two-year period ended March 18, 2016. The Company determined that the $1,500 upfront payment should be recognized as revenue ratably over the expected period of performance, being the two-year period ended March 18, 2016.            
Sales Based Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from milestone payments   $ 0              
Teva [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable               $ 335,000,000  
Proceeds from milestone payments   0              
Teva [Member] | Clinical Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable               20,000,000  
Teva [Member] | Regulatory Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable               285,000,000  
Teva [Member] | Sales Based Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable               30,000,000  
Teva [Member] | TV-45070 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from upfront fee               $ 41,000,000  
Genentech [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from upfront fee $ 1,500,000                
Potential Milestone Payments Receivable 1,750,000               $ 613,000,000
Proceeds from milestone payments   0   $ 250,000          
Genentech [Member] | Regulatory Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable                 387,500,000
Genentech [Member] | Sales Based Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable                 180,000,000
Genentech [Member] | Preclinical And Clinical Milestone [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable                 45,500,000
Genentech [Member] | Preclinical Clinical and Regulatory Milestones [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from milestone payments   $ 0   $ 0   $ 8,000,000      
Genentech [Member] | GDC-0276 [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from upfront fee                 $ 10,000,000
Genentech Affiliate [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from Issuance of Private Placement $ 4,455,000                
uniQure [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Proceeds from milestone payments | CAD     CAD 0   CAD 0   CAD 0    
uniQure [Member] | Glybera [Member]                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                  
Potential Milestone Payments Receivable | CAD     CAD 1,000,000